0.9% Sodium Chloride, JNJ-78901563
VAC52416BAC3001
Phase 3 small_molecule active
Quick answer
0.9% Sodium Chloride, JNJ-78901563 for Invasive Extraintestinal Pathogenic Escherichia coli Disease is a Phase 3 program (small_molecule) at Janssen Pharmaceutica N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen Pharmaceutica N.V.
- Indication
- Invasive Extraintestinal Pathogenic Escherichia coli Disease
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active